BioCardia (BCDA) Revenue Growth (1y) (2012 - 2024)
Powered by 
Analysis
BioCardia (BCDA) Revenue Growth (1y) (2012 - 2024) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Krystal Biotech | 10.21 Bn | 9.36 Bn | 112.79 Mn | 24.14% |
| 2 | CRISPR Therapeutics AG | 5.05 Bn | 5.05 Bn | - | - |
| 3 | Iovance Biotherapeutics | 3.74 Bn | 3.45 Bn | 55.72 Mn | 65.65% |
| 4 | Legend Biotech | 3.57 Bn | 2.61 Bn | 251.50 Mn | 51.90% |
| 5 | uniQure | 3.00 Bn | 3.00 Bn | 5.49 Mn | - |
| 6 | Beam Therapeutics | 2.55 Bn | 2.55 Bn | - | - |
| 7 | Precigen | 2.36 Bn | 2.36 Bn | 52.17 Mn | - |
| 8 | Sarepta Therapeutics | 2.21 Bn | 1.42 Bn | 251.87 Mn | -34.34% |
| 9 | Vericel | 1.95 Bn | 1.79 Bn | 56.40 Mn | 22.48% |
| 10 | BioCardia | 13.18 Mn | 9.06 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2024 | -93.02% |
| Mar 31, 2024 | -14.06% |
| Dec 31, 2023 | -87.74% |
| Sep 30, 2023 | 68.40% |
| Jun 30, 2023 | -95.59% |
| Mar 31, 2023 | 6.67% |
| Dec 31, 2022 | 34.18% |
| Sep 30, 2022 | -74.18% |
| Jun 30, 2022 | 1,311.59% |
| Mar 31, 2022 | 30.43% |
| Dec 31, 2021 | 71.74% |
| Sep 30, 2021 | 2,314.71% |
| Jun 30, 2021 | 155.56% |
| Mar 31, 2021 | 21.05% |
| Dec 31, 2020 | -78.60% |
| Sep 30, 2020 | -82.47% |
| Jun 30, 2020 | -68.60% |
| Mar 31, 2020 | -82.41% |
| Dec 31, 2019 | 108.74% |
| Sep 30, 2019 | 130.95% |